Chesapeake Capital Corp IL Makes New $448,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Chesapeake Capital Corp IL purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 3,350 shares of the life sciences company's stock, valued at approximately $448,000.

Other institutional investors have also recently made changes to their positions in the company. Empowered Funds LLC lifted its position in Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock worth $516,000 after buying an additional 66 shares during the last quarter. Bank of Stockton raised its stake in shares of Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after acquiring an additional 80 shares in the last quarter. Caprock Group LLC lifted its holdings in shares of Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock worth $376,000 after acquiring an additional 83 shares during the last quarter. Stephens Inc. AR boosted its stake in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock valued at $885,000 after purchasing an additional 90 shares in the last quarter. Finally, Moors & Cabot Inc. boosted its stake in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock valued at $759,000 after purchasing an additional 95 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Up 3.4 %

Illumina stock traded up $2.87 on Friday, hitting $87.66. 3,822,397 shares of the stock traded hands, compared to its average volume of 2,097,701. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The firm has a market cap of $13.89 billion, a P/E ratio of -11.41, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business's fifty day simple moving average is $108.20 and its 200 day simple moving average is $128.27.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Citigroup reduced their price target on Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Stephens reaffirmed an "overweight" rating and issued a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Finally, Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.